| Date | Title | Description |
| 12.02.2025 | TECLens Secures $9.3 Million to Revolutionize Vision Correction | In a bold move that could reshape the landscape of vision correction, TECLens, a clinical-stage ophthalmic medical device company based in Stamford, Connecticut, has successfully raised $9.3 million in Series A funding. This round was co-le... |
| 11.02.2025 | TECLens Raises $9.3M Series A Funding | TECLens, a Stamford, CT-based clinical-stage ophthalmic medical device company, raised $9.3M in Series A funding.
The round was led by Johnson & Johnson Innovation – JJDC Inc. and Yonjin Capital, with participation from Rimonci Capital,... |
| 11.02.2025 | TECLens: $9.3 Million (Series A) Raised For Advancing Non-Invasive Refractive Technology | TECLens, a clinical-stage ophthalmic medical device company, announced it raised $9.3 million in a Series A round co-led by Johnson & Johnson Innovation – JJDC Inc. and Yonjin Capital. And other investors include Rimonci Capital and Sun... |
| 08.01.2024 | TECLens Chooses Validcare as CRO for its Presbyopia Study | Validcare’s approach is tailored to meet the regulatory and budgetary needs of small biotech.
Validcare’s approach to data collection and data management provides us the flexibility that is critical to us in this early stage of development.... |
| - | TECLens | “TECLens – The Future of Vision Correction” |
